Sbir phase II: covid-19 rapid sensing using structural DNA biosensors

Ended Cooperative Agreement Awarded Last action

Award ID
2127436
Recipient
Awarding agency
Obligated
$998,507

Award facts

Completion date
Originally
Place of performance
Cary, NC 27519, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The broader impact of this small business innovation research (sbir) phase i project will be the development of a platform technology for creating rapid virus diagnostics that directly recognizes the virus surface protein pattern from a patient sample and generates accurate results within minutes. Current standards for high-fidelity viral pathogen diagnostics require complex instruments, technical expertise to run the instruments, and hours to produce and interpret results. The proposed platform creates a virus-specific biosensor that selectively binds to the target virus and produces visible results without time-consuming pre-processing or expensive instruments. Lower cost tests and faster sample-to-result turnovers could result in more effective control of disease spread. This project seeks to develop a highly functional, sensitive, and specific diagnostic for the detection of coronavirus. This technology is based on the company?s pattern-recognition enhanced sensing and therapeutics (pest) concept. The solution is a first-in-class diagnostics that uses algorithmically-designed structural DNA to form a trap that may detect and selectively bind a signature pattern of the pathogen. This recognition and binding may generate visual signals without the need of DNA/RNA preprocessing or amplification associated with the current generation of molecular tests (polymerase chain reactions, pcrs). This project will involve building a preclinical prototype of pest-enabled lateral flow based covid-19 rapid diagnostics with a goal of providing results for each sample within 5 minutes. This fast test result will be followed by preclinical validation to determine the test?s specificity, limits of detection, and implement mechanism to improve the assay specificity and to avoid cross-reaction to other virus types. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.

Transactions

Action Obligated Date
Amendment $0
Original award $998,507

Quick answers

Who received award 2127436?

2127436 was awarded to Atom Bioworks Inc. by National Science Foundation on August 1, 2022.

How much is award 2127436 worth?

$998,507 has been obligated on 2127436.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login